<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; focus</title>
	<atom:link href="http://www.tapanray.in/tag/focus/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Focus On All 3 Areas of Innovation For Affordable Access To Innovative Drugs</title>
		<link>http://www.tapanray.in/focus-on-all-3-areas-of-innovation-for-affordable-access-to-innovative-drugs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=focus-on-all-3-areas-of-innovation-for-affordable-access-to-innovative-drugs</link>
		<comments>http://www.tapanray.in/focus-on-all-3-areas-of-innovation-for-affordable-access-to-innovative-drugs/#comments</comments>
		<pubDate>Mon, 29 Nov 2021 00:00:53 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[ace]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[changing]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[differential]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[focus]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[Issues]]></category>
		<category><![CDATA[Models]]></category>
		<category><![CDATA[outcomesbusiness]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[problem]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[solution]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[three areas]]></category>
		<category><![CDATA[tiered]]></category>
		<category><![CDATA[win-win]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10615</guid>
		<description><![CDATA[Medical treatment has made astonishing advances over the years. But the packaging and delivery of that treatment are often inefficient, ineffective, and consumer unfriendly. This was articulated in an article on innovation in healthcare, published in the Harvard Business Review, way &#8230; <a href="http://www.tapanray.in/focus-on-all-3-areas-of-innovation-for-affordable-access-to-innovative-drugs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/focus-on-all-3-areas-of-innovation-for-affordable-access-to-innovative-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Focus On Core Competencies &#8211; Regardless of Generic Or Innovative Drug Business</title>
		<link>http://www.tapanray.in/focus-on-core-competencies-regardless-of-generic-or-innovative-drug-business/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=focus-on-core-competencies-regardless-of-generic-or-innovative-drug-business</link>
		<comments>http://www.tapanray.in/focus-on-core-competencies-regardless-of-generic-or-innovative-drug-business/#comments</comments>
		<pubDate>Mon, 22 Feb 2021 00:00:23 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[antibiotics]]></category>
		<category><![CDATA[brands]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Carving-out]]></category>
		<category><![CDATA[cephalosporin]]></category>
		<category><![CDATA[cephalosporins]]></category>
		<category><![CDATA[competencies]]></category>
		<category><![CDATA[core]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[focus]]></category>
		<category><![CDATA[Fortum]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[normal]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Old]]></category>
		<category><![CDATA[perspective]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regardless]]></category>
		<category><![CDATA[Relevance]]></category>
		<category><![CDATA[Sandoz]]></category>
		<category><![CDATA[shifting]]></category>
		<category><![CDATA[Spin-offs]]></category>
		<category><![CDATA[Splitting-off]]></category>
		<category><![CDATA[Strategic]]></category>
		<category><![CDATA[strength]]></category>
		<category><![CDATA[success]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Zinacef]]></category>
		<category><![CDATA[Zinnat]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10421</guid>
		<description><![CDATA[On February 11, 2021, by two different Press Releases, two global pharma majors – GSK and Novartis simultaneously made interesting announcements. Both were related to three generic cephalosporin antibiotics. GSK revealed, ‘it has reached an agreement with Sandoz &#8211; a &#8230; <a href="http://www.tapanray.in/focus-on-core-competencies-regardless-of-generic-or-innovative-drug-business/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/focus-on-core-competencies-regardless-of-generic-or-innovative-drug-business/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Shift from Disease Centered Care To Patient-Goals Directed Care In The New Normal</title>
		<link>http://www.tapanray.in/shift-from-disease-centered-care-to-patient-goals-directed-care-in-the-new-normal/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=shift-from-disease-centered-care-to-patient-goals-directed-care-in-the-new-normal</link>
		<comments>http://www.tapanray.in/shift-from-disease-centered-care-to-patient-goals-directed-care-in-the-new-normal/#comments</comments>
		<pubDate>Sun, 09 Aug 2020 23:50:04 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[cases]]></category>
		<category><![CDATA[centered]]></category>
		<category><![CDATA[centricity]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[directed]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[focus]]></category>
		<category><![CDATA[goal]]></category>
		<category><![CDATA[GPs]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[normal]]></category>
		<category><![CDATA[Old]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[physicians]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[shift]]></category>
		<category><![CDATA[specialists]]></category>
		<category><![CDATA[story]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[treatment]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10218</guid>
		<description><![CDATA[In the initial days of the first quarter of 2020, no one could fathom that just within the next 4 months over two million fellow citizens will get infected by an unknown virus, recording over 45,500 deaths. Many authorities may &#8230; <a href="http://www.tapanray.in/shift-from-disease-centered-care-to-patient-goals-directed-care-in-the-new-normal/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/shift-from-disease-centered-care-to-patient-goals-directed-care-in-the-new-normal/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Drug Pricing: Why Justify On R&amp;D Cost Rather Than Precise ‘Customer Value’?</title>
		<link>http://www.tapanray.in/drug-pricing-why-justify-on-rd-cost-rather-than-precise-customer-value/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=drug-pricing-why-justify-on-rd-cost-rather-than-precise-customer-value</link>
		<comments>http://www.tapanray.in/drug-pricing-why-justify-on-rd-cost-rather-than-precise-customer-value/#comments</comments>
		<pubDate>Mon, 16 Dec 2019 00:00:05 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[connects]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[eclectic]]></category>
		<category><![CDATA[electronics]]></category>
		<category><![CDATA[emotional]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[focus]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[justification]]></category>
		<category><![CDATA[justify]]></category>
		<category><![CDATA[lawsuit]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[monetary]]></category>
		<category><![CDATA[offerings]]></category>
		<category><![CDATA[Oregon]]></category>
		<category><![CDATA[prices]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[unique]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9815</guid>
		<description><![CDATA[While looking around, it won’t be difficult to spot many types of steep-priced highly innovative products, where high costs aren’t justified by high R&#38;D expenditure, but for unique ‘customer value’ offerings. Many consumers evaluate those and decide to settle for &#8230; <a href="http://www.tapanray.in/drug-pricing-why-justify-on-rd-cost-rather-than-precise-customer-value/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/drug-pricing-why-justify-on-rd-cost-rather-than-precise-customer-value/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>On The Flip Side of Pharma Industry: A Saga of Perennial Contradictions</title>
		<link>http://www.tapanray.in/on-the-flip-side-of-pharma-industry-a-saga-of-perennial-contradictions/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=on-the-flip-side-of-pharma-industry-a-saga-of-perennial-contradictions</link>
		<comments>http://www.tapanray.in/on-the-flip-side-of-pharma-industry-a-saga-of-perennial-contradictions/#comments</comments>
		<pubDate>Mon, 09 Dec 2019 00:00:48 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[CEOs]]></category>
		<category><![CDATA[contradiction]]></category>
		<category><![CDATA[contradictions]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[diseases]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[facet]]></category>
		<category><![CDATA[flip]]></category>
		<category><![CDATA[focus]]></category>
		<category><![CDATA[gene]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[implementation]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[investment]]></category>
		<category><![CDATA[perennial]]></category>
		<category><![CDATA[prices]]></category>
		<category><![CDATA[primary]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[rare]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Saga]]></category>
		<category><![CDATA[Senate]]></category>
		<category><![CDATA[shift]]></category>
		<category><![CDATA[side]]></category>
		<category><![CDATA[strategies]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapy]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[vice versa]]></category>
		<category><![CDATA[Voluntary]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9804</guid>
		<description><![CDATA[Awesome contribution in the battle against multiple diseases, is obviously the primary facet of the pharma industry. However, on its flip side, one would witness a saga of numerous contradictions. Some of these exist perennially in well-protected opaque cocoons, regardless &#8230; <a href="http://www.tapanray.in/on-the-flip-side-of-pharma-industry-a-saga-of-perennial-contradictions/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/on-the-flip-side-of-pharma-industry-a-saga-of-perennial-contradictions/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Disruptive Impact of AI on Pharma Sales And Marketing</title>
		<link>http://www.tapanray.in/disruptive-impact-of-ai-on-pharma-sales-and-marketing/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=disruptive-impact-of-ai-on-pharma-sales-and-marketing</link>
		<comments>http://www.tapanray.in/disruptive-impact-of-ai-on-pharma-sales-and-marketing/#comments</comments>
		<pubDate>Mon, 15 Jul 2019 00:00:31 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[applications]]></category>
		<category><![CDATA[Artificial]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[creative]]></category>
		<category><![CDATA[Disruptive]]></category>
		<category><![CDATA[focus]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Intelligence]]></category>
		<category><![CDATA[KOL]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[people]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[platforms]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[replace]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[tools]]></category>
		<category><![CDATA[transformation]]></category>
		<category><![CDATA[transformative]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9629</guid>
		<description><![CDATA[Artificial Intelligence (AI) that refers to the ability of machines to perform cognitive tasks like thinking, perceiving, learning, problem solving and decision making, is poised to disrupt our world. Initially conceived as a technology that could mimic human intelligence, AI &#8230; <a href="http://www.tapanray.in/disruptive-impact-of-ai-on-pharma-sales-and-marketing/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/disruptive-impact-of-ai-on-pharma-sales-and-marketing/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Focus On Patient Compliance To Boost Pharma Sales…And More…</title>
		<link>http://www.tapanray.in/focus-on-patient-compliance-to-boost-pharma-salesand-more/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=focus-on-patient-compliance-to-boost-pharma-salesand-more</link>
		<comments>http://www.tapanray.in/focus-on-patient-compliance-to-boost-pharma-salesand-more/#comments</comments>
		<pubDate>Mon, 20 May 2019 00:00:41 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Apple]]></category>
		<category><![CDATA[apps]]></category>
		<category><![CDATA[Asthma]]></category>
		<category><![CDATA[barrier]]></category>
		<category><![CDATA[Blockchain]]></category>
		<category><![CDATA[boost]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[chronic]]></category>
		<category><![CDATA[Compliance]]></category>
		<category><![CDATA[COPD]]></category>
		<category><![CDATA[diabetes]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[diseases]]></category>
		<category><![CDATA[driver]]></category>
		<category><![CDATA[drug companies]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[financial]]></category>
		<category><![CDATA[focus]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[increase]]></category>
		<category><![CDATA[Leveraging]]></category>
		<category><![CDATA[new products]]></category>
		<category><![CDATA[non-adherence]]></category>
		<category><![CDATA[noncompliance]]></category>
		<category><![CDATA[out of pocket]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[patient-compliance]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[smartphone]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9534</guid>
		<description><![CDATA[One high-impact area in the healthcare space that often finds its place in the backseat is &#8211; patient noncompliance. A term that is commonly used in regard to ‘a patient who does not take a prescribed medication or follow a prescribed course &#8230; <a href="http://www.tapanray.in/focus-on-patient-compliance-to-boost-pharma-salesand-more/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/focus-on-patient-compliance-to-boost-pharma-salesand-more/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma Marketing: Time For A Disruptive Change with A New Breed of Marketers</title>
		<link>http://www.tapanray.in/pharma-marketing-time-for-a-disruptive-change-with-a-new-breed-of-marketers/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-marketing-time-for-a-disruptive-change-with-a-new-breed-of-marketers</link>
		<comments>http://www.tapanray.in/pharma-marketing-time-for-a-disruptive-change-with-a-new-breed-of-marketers/#comments</comments>
		<pubDate>Mon, 11 Mar 2019 00:00:51 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[breed]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Change]]></category>
		<category><![CDATA[demands]]></category>
		<category><![CDATA[Disruptive]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[environmental]]></category>
		<category><![CDATA[focus]]></category>
		<category><![CDATA[fundamental]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[marketer]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[persona]]></category>
		<category><![CDATA[personality]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[pull]]></category>
		<category><![CDATA[Push]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[role]]></category>
		<category><![CDATA[services]]></category>
		<category><![CDATA[shift]]></category>
		<category><![CDATA[success]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9440</guid>
		<description><![CDATA[In Today’s fast-changing world, as I indicated in several of my previous articles, more and more people first try to understand the causative factors of their ailments, and options available for effective remedial measures. They strive to get such information, &#8230; <a href="http://www.tapanray.in/pharma-marketing-time-for-a-disruptive-change-with-a-new-breed-of-marketers/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-marketing-time-for-a-disruptive-change-with-a-new-breed-of-marketers/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma’s Oncology Focus: Some Key Drivers With Pros And Cons For Patients</title>
		<link>http://www.tapanray.in/pharmas-oncology-focus-some-key-drivers-with-pros-and-cons-for-patients/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharmas-oncology-focus-some-key-drivers-with-pros-and-cons-for-patients</link>
		<comments>http://www.tapanray.in/pharmas-oncology-focus-some-key-drivers-with-pros-and-cons-for-patients/#comments</comments>
		<pubDate>Mon, 28 Jan 2019 00:00:03 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[acquisition]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[Bristol]]></category>
		<category><![CDATA[Bristol-Myers Squibb]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[Celgene]]></category>
		<category><![CDATA[cons]]></category>
		<category><![CDATA[drivers]]></category>
		<category><![CDATA[focus]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[M&A]]></category>
		<category><![CDATA[Myers]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[pros]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[TRK inhibitor]]></category>
		<category><![CDATA[Vitrakvi]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9391</guid>
		<description><![CDATA[Just in the first ten days of the brand-new year &#8211; 2019, three important oncology focused acquisitions were announced by three top global pharma companies. On January 03, 2019, Bristol-Myers Squibb announced that it will acquire Celgene for a hefty sum of USD &#8230; <a href="http://www.tapanray.in/pharmas-oncology-focus-some-key-drivers-with-pros-and-cons-for-patients/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharmas-oncology-focus-some-key-drivers-with-pros-and-cons-for-patients/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>For Patient-Centricity: Emerging a C-Suite Role</title>
		<link>http://www.tapanray.in/for-patient-centricity-emerging-a-c-suite-role/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=for-patient-centricity-emerging-a-c-suite-role</link>
		<comments>http://www.tapanray.in/for-patient-centricity-emerging-a-c-suite-role/#comments</comments>
		<pubDate>Mon, 20 Aug 2018 00:00:40 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[attributes]]></category>
		<category><![CDATA[C-suite]]></category>
		<category><![CDATA[centric]]></category>
		<category><![CDATA[centricity]]></category>
		<category><![CDATA[Chief]]></category>
		<category><![CDATA[consistently]]></category>
		<category><![CDATA[CPO]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[focus]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[LEO]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[multi-channel]]></category>
		<category><![CDATA[Officer]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[pillars]]></category>
		<category><![CDATA[platforms]]></category>
		<category><![CDATA[products]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9110</guid>
		<description><![CDATA[Regardless of skepticism of many, the formidable power of physicians to take all treatment decisions for patients, is gradually getting moderated, globally. Although, its pace may vary from country to country. An increasing number of more informed patients are carving &#8230; <a href="http://www.tapanray.in/for-patient-centricity-emerging-a-c-suite-role/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/for-patient-centricity-emerging-a-c-suite-role/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
